Delving into the Latest Updates on Beijing Cotimes Biotech Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Monoclonal antibody	1

Top 5 Target	Count

DR5(Tumor necrosis factor receptor superfamily member 10B)	1

主要目的：探索重组抗人DR5单克隆抗体注射液单药治疗晚期实体肿瘤的安全性与耐受性；次要目的：评估重组抗人DR5单克隆抗体注射液单药治疗晚期实体肿瘤的药代动力学特征；初步评估重组抗人DR5单克隆抗体注射液治疗晚期实体肿瘤的抗肿瘤活性；评估重组抗人DR5单克隆抗体注射液的免疫原性；

[Translation]

Primary purpose: To explore the safety and tolerability of recombinant anti-human DR5 monoclonal antibody injection as a monotherapy for advanced solid tumors; Secondary purpose: To evaluate the pharmacokinetic characteristics of recombinant anti-human DR5 monoclonal antibody injection as a monotherapy for advanced solid tumors; To preliminarily evaluate the antitumor activity of recombinant anti-human DR5 monoclonal antibody injection in the treatment of advanced solid tumors; To evaluate the immunogenicity of recombinant anti-human DR5 monoclonal antibody injection;

Start Date25 Jul 2018

Sponsor / Collaborator

Lonn Ryonn PHARMA Ltd.

[+1]

100 Clinical Results associated with Beijing Cotimes Biotech Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Beijing Cotimes Biotech Co., Ltd.

Login to view more data

100 Deals associated with Beijing Cotimes Biotech Co., Ltd.

Login to view more data

100 Translational Medicine associated with Beijing Cotimes Biotech Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Recombinant anti-human DR5 monoclonal antibody(Beijing Tongwei Shidai Shengwu Jishu Youxian Gongsi) ( DR5 )	Advanced Malignant Solid Neoplasm More	Phase 1